Roth MKM analyst Boobalan Pachaiyappan lowered the firm’s price target on Entrada Therapeutics (TRDA) to $23 from $29 and keeps a Buy rating on ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Entrada Therapeutics Inc (TRDA – Research ...

Entrada Therapeutics (TRDA) delivered earnings and revenue surprises of 104.55% and 173.66%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the ...

Entrada Therapeutics' innovative Endosomal Escape Vehicle platform, poised to revolutionize drug delivery. Click here to read ...

Entrada Therapeutics (NASDAQ:TRDA – Get Free Report)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a note issued to investors on Tuesday,Benzinga reports. They currently have ...

Entrada Therapeutics gains FDA clearance for its Phase 1b ELEVATE-44-102 study, evaluating ENTR-601-44 in adult Duchenne ...

Entrada Therapeutics can plough on with the development of its Duchenne muscular dystrophy (DMD) therapy, ENTR-601-44, now ...

Receives FDA authorization to initiate ELEVATE-44-102, a Phase 1b multiple ascending dose clinical study of ENTR-601-44 in adults living with Duchenne muscular dystrophy - - Follows recently received ...

BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that the United States Food and Drug Administration (FDA) has lifted the clinical hold on ENTR ...

- Expands global ELEVATE-44 clinical program to include pediatric, adult, ambulatory and non-ambulatory patients with Duchenne muscular dystrophy - ...

Following a more than two-year-long hold, Entrada Therapeutics can get its Duchenne muscular dystrophy candidate back on ...